Product manufactured at facility approved by Australia’s Therapeutic Goods Administration

The drug is also prescribed for Parkinson's disease

Renata PLC, one of the country’s leading pharmaceutical companies, discontinued nearly 30 percent of its product line in the last fiscal year after production costs outpaced selling prices, according to the company’s chief executive officer (CEO).

The listed drugmaker made Tk 58 crore in the January-March quarter

The pharmaceuticals will be commercialised under Renata’s branding

Higher wages and currency depreciation caused the profit to fall

The tablet, Risperidone, is locally marketed as Sperid

Renata PLC has raised Tk 536 crore by issuing zero coupon bonds and preference shares, saying the funds would be used to reduce its average cost of lending. 

The shares are issued to refinance existing loans 

Increased spending on raw material, manpower caused the fall

The contraceptive pill named Levonorgestrel 1.5 mg is known by its brand name of Novella-1

The drugmaker’s nine months’ profit exceeds FY22’s full year figure